Status:
COMPLETED
Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity
Lead Sponsor:
University of Rochester
Conditions:
Lung Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
This study is being conducted by the University of Rochester Cancer Center to determine the levels of cytokines in the blood, and to determine if blood levels of these cytokines are related to the sid...
Eligibility Criteria
Inclusion
- Patients receiving radiation therapy for lung cancer combined with surgery either pre or post RT to the chest for lung cancer not associated with atelectasis, pleural effusion.
- Patients receiving HDR Brachytherapy for lung cancer.
- Patients receiving concomitant radiation and interferon therapy for lung cancer.
- Patients receiving concomitant chemotherapy and radiation for lung cancer. Prior drug therapy does not make patients ineligible.
- Karnofsky ≥ 70 %.
- There are no age restrictions.
- Acceptable bone marrow function - WBC 2 3000/mm3, platelet count \> 100,000, hematocrit ≥ 33%, hemoglobin ≥ 11 gms/dl.
- Life expectancy \> 6 months.
- Patients must sign informed consent meeting all federal and institutional guidelines.
Exclusion
- Patients not meeting eligibility criteria stated above
Key Trial Info
Start Date :
March 15 1996
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 25 2013
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00178230
Start Date
March 15 1996
End Date
November 25 2013
Last Update
June 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rochester, Dept. Radiation Oncology
Rochester, New York, United States, 14642